In part 2, the debaters map the trial that could settle the question and agree that, for now, individualized care and closer monitoring should guide high-risk early MF.
Jade Cury-Martins, MD, PhD
Advertisement
Articles by Jade Cury-Martins, MD, PhD
In the beginning of a two-part debate, two experts agree the evidence to treat poor-prognosis early MF differently from the onset isn’t here yet.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
4
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
5